Innovative design of bacterial outer membrane vesicles for vaccine development
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Bacterial Infections and Vaccines · SARS-CoV-2 and COVID-19 Research · Virology and Viral Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Vaccine hesitancy: definition, scope and determinants10.1016/j.vaccine.2015.04.036 ↗
2. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications10.1586/14760584.2015.964212 ↗
3. Current and next generation influenza vaccines: formulation and production strategies10.1016/j.ejpb.2015.05.023 ↗
4. Cancer vaccines as promising immuno-therapeutics: platforms and current progress10.1186/s13045-022-01247-x ↗
5. Bacterial outer membrane vesicles suppress tumor by interferon-γ- mediated antitumor response10.1038/s41467-017-00729-8 ↗
6. Bacterial membrane vesicles for vaccine applications10.1016/j.addr.2022.114294 ↗
7. Gram-negative outer membrane vesicles in vaccine development
8. Types and origins of bacterial membrane vesicles10.1038/s41579-018-0112-2 ↗
9. Outer membrane vesicles (OMVs) produced by gram-negative bacteria: structure, functions, biogenesis, and vaccine application10.1155/2021/1490732 ↗
10. Outer membrane vesicles (OMVs) of gram-negative bacteria: a perspective update10.3389/fmicb.2017.01053 ↗
11. Outer membrane vesicles: an emerging vaccine platform10.3390/vaccines10101578 ↗
12. Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy10.3390/cancers11091314 ↗
13. Bioengineering bacterial outer membrane vesicles as vaccine platform10.1016/j.biotechadv.2017.05.003 ↗
14. Approaches to surface engineering of extracellular vesicles10.1016/j.addr.2021.03.020 ↗
15. Strategies to tackle antimicrobial resistance: the example of Escherichia coli and Pseudomonas aeruginosa10.3390/ijms22094943 ↗
16. Bacterial outer membrane vesicles: from discovery to applications10.1146/annurev-micro-052821-031444 ↗
17. Bacterial outer membrane vesicles as a versatile tool in vaccine research and the fight against antimicrobial resistance10.1128/mBio.01707-21 ↗
18. Bacterial membrane vesicles: physiological roles, infection immunology, and applications10.1002/advs.202301357 ↗
19. Nanotechnology in vaccine delivery10.1016/j.addr.2007.05.017 ↗
20. Nanotechnology and vaccine development
21. Emerging vaccine nanotechnology: from defense against infection to sniping cancer10.1016/j.apsb.2021.12.021 ↗
22. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment10.1038/s41392-024-01745-z ↗
23. Biological nanoparticles in vaccine development10.3389/fbioe.2022.867119 ↗
24. Bacterial outer membrane vesicles as a platform for biomedical applications: an update10.1016/j.jconrel.2020.04.031 ↗
25. Outer membrane vesicles of gram-negative bacteria: an outlook on biogenesis10.3389/fmicb.2021.557902 ↗
26. Biogenesis and multifaceted roles of outer membrane vesicles from Gram-negative bacteria10.1099/mic.0.079400-0 ↗
27. Microbial biosynthesis of designer outer membrane vesicles10.1016/j.copbio.2014.02.018 ↗
28. Biological functions and biogenesis of secreted bacterial outer membrane vesicles, in: S. Gottesman, C.S. Harwood (Eds.)10.1146/annurev.micro.091208.073413 ↗
29. Outer Membrane Vesicles: Biogenesis, Functions, And Issues10.1128/mmbr.00032-22 ↗
30. Association of cholera toxin with Vibrio cholerae outer membrane vesicles which are internalized by human intestinal epithelial cells10.1016/j.febslet.2011.04.017 ↗
31. Environmentally controlled bacterial vesicle-mediated export10.1111/cmi.12676 ↗
32. Bacterial extracellular vesicles: modulation of biofilm and virulence properties10.1016/j.actbio.2024.02.029 ↗
33. Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: Intracellular delivery, trafficking and mechanisms of cell injury10.1371/journal.ppat.1006159 ↗
34. Bacterial membrane vesicle functions, laboratory methods, and applications10.1016/j.biotechadv.2021.107869 ↗
35. Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious/inflammatory diseases10.1038/aps.2017.82 ↗
36. Availability of iron ions impacts physicochemical properties and proteome of outer membrane vesicles released by Neisseria gonorrhoeae10.1038/s41598-023-45498-1 ↗
37. Iron influences the expression of Helicobacter pylori outer membrane vesicle-associated virulence factors10.1097/00042737-200012120-00002 ↗
38. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles10.1016/j.vaccine.2005.01.055 ↗
39. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development10.1371/journal.pone.0054314 ↗
40. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria10.1016/j.micres.2014.09.006 ↗
41. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development10.1371/journal.pone.0054314 ↗
42. Antibiotic-mediated modulations of outer membrane vesicles in enterohemorrhagic Escherichia coli O104:H4 and O157:H710.1128/AAC.00937-17 ↗
43. Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based10.1186/s13000-018-0768-y ↗
44. Biomimetic nanoparticles coated with bacterial outer membrane vesicles as a new-generation platform for biomedical applications10.3390/pharmaceutics13111887 ↗
45. Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli10.1002/pmic.200700196 ↗
46. Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles10.1074/jbc.M307628200 ↗
47. Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine10.1021/pr1009756 ↗
48. Proteomics in gram-negative bacterial outer membrane vesicles10.1002/mas.20175 ↗
49. Quantitative and qualitative preparations of bacterial outer membrane vesicles10.1007/978-1-62703-245-2_16 ↗
50. The effect of growth stage and isolation method on properties of ClearColi™ outer membrane vesicles (OMVs)10.1007/s00284-021-02414-y ↗
51. Effective platform for the production of recombinant outer membrane vesicles in gram-negative bacteria10.4014/jmb.2003.03023 ↗
52. Outer membrane vesicle induction and isolation for vaccine development10.3389/fmicb.2021.629090 ↗
53. Mass-produced gram-negative bacterial outer membrane vesicles activate cancer antigen-specific stem-like CD8+ T cells which enables an effective combination immunotherapy with anti-PD-110.1002/jev2.12357 ↗
54. Molecular characterization of outer membrane vesicles released from Acinetobacter radioresistens and their potential roles in pathogenesis10.1016/j.micpath.2015.04.005 ↗
55. Proteomic analysis of outer membrane proteins and vesicles of a clinical isolate and a collection strain of Stenotrophomonas maltophilia10.1016/j.jprot.2016.05.001 ↗
56. Isolation and proteomic characterization of bacterial extracellular membrane vesicles10.2174/1573403X10666140505163121 ↗
57. Characterization of outer membrane vesicles from a neonatal meningitic strain of Cronobacter sakazakii10.1093/femsle/fnv085 ↗
58. Isolation of outer membrane vesicles including their quantitative and qualitative analyses10.1007/978-1-4939-8685-9_11 ↗
59. Proteome analysis of mitochondrial outer membrane from Neurospora crassa10.1002/pmic.200402084 ↗
60. Engineered extracellular vesicles and their mimetics for cancer immunotherapy10.1016/j.jconrel.2022.05.062 ↗
61. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy10.1021/nn405724x ↗
62. Adjuvants: classification, modus operandi, and licensing10.1155/2016/1459394 ↗
63. Outer membrane vesicles (OMVs) enabled bio-applications: a critical review10.1002/bit.27965 ↗
64. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery10.1038/s41596-022-00713-7 ↗
65. Engineered bacteria enhance immunotherapy and targeted therapy through stromal remodeling of tumors
66. Immune checkpoint inhibitors in cancer therapy10.3390/curroncol29050247 ↗
67. Predictive biomarkers for checkpoint inhibitor-based immunotherapy10.1016/S1470-2045(16)30406-5 ↗
68. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma10.1186/s13046-019-1085-3 ↗
69. Self-blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy10.1002/adma.202106307 ↗
70. Glycoengineered outer membrane vesicles as a platform for vaccine development10.1016/bs.mie.2017.06.032 ↗
71. Dynamic shielding of bacterial outer membrane vesicles for safe and efficient chemo-immunotherapy against tumors10.1007/s12274-023-6225-6 ↗
72. Targeting pyroptosis through lipopolysaccharide-triggered noncanonical pathway for safe and efficient cancer immunotherapy10.1021/acs.nanolett.3c02728 ↗
73. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention10.1021/acs.nanolett.9b02182 ↗
74. Redirecting antigens by engineered photosynthetic bacteria and derived outer membrane vesicles for enhanced cancer immunotherapy10.1021/acsnano.3c01912 ↗
75. Sequentially triggered bacterial outer membrane vesicles for macrophage metabolism modulation and tumor metastasis suppression10.1021/acsnano.1c05613 ↗
76. Antigen capture and immune modulation by bacterial outer membrane vesicles as in situ vaccine for cancer immunotherapy post-photothermal therapy10.1002/smll.202107461 ↗
77. Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity10.1038/s41467-023-37369-0 ↗
78. Bacterial outer membrane vesicle nanorobot10.1073/pnas.2403460121 ↗
79. Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy
80. Metal-polyphenol "prison" attenuated bacterial outer membrane vesicle for chemodynamics promoted in situ tumor vaccines10.1016/j.biomaterials.2023.122396 ↗
81. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy
82. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy10.1038/s41467-023-38679-z ↗
83. Bioengineered bacterial membrane vesicles with multifunctional nanoparticles as a versatile platform for cancer immunotherapy10.1021/acsami.2c18244 ↗
84. Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy
85. Recent advances in biomedical applications of bacterial outer membrane vesicles10.1039/D2TB00683A ↗
86. A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy10.1186/s12951-021-01193-9 ↗
87. Hybrid vesicles based on autologous tumor cell membrane and bacterial outer membrane to enhance innate immune response and personalized tumor immunotherapy10.1021/acs.nanolett.1c02482 ↗
88. Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity10.1016/j.nantod.2020.101007 ↗
89. Phytochemical engineered bacterial outer membrane vesicles for photodynamic effects promoted immunotherapy10.1021/acs.nanolett.2c01280 ↗
90. Bacterial vesicle-cancer cell hybrid membrane-coated nanoparticles for tumor specific immune activation and photothermal therapy10.1021/acsami.0c13169 ↗
91. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism10.1016/j.jconrel.2019.11.017 ↗
92. Cloaking mesoporous polydopamine with bacterial membrane vesicles to amplify local and systemic antitumor immunity10.1021/acsnano.3c00363 ↗
93. Bacterial outer membrane vesicles as cationic dye carriers for optoacoustics-guided phototherapy of cancer10.1186/s12645-023-00191-w ↗
94. Bacterial outer membrane vesicle-templated biomimetic nanoparticles for synergistic photothermo-immunotherapy10.1016/j.nantod.2022.101591 ↗
95. Salmonella-mediated blood-brain barrier penetration, tumor homing and tumor microenvironment regulation for enhanced chemo/bacterial glioma therapy10.1016/j.apsb.2022.09.016 ↗
96. Physical disruption of solid tumors by immunostimulatory microrobots enhances antitumor immunity10.1002/adma.202103505 ↗
97. Innovative utilization of cell membrane-coated nanoparticles in precision cancer therapy10.1002/EXP.20230164 ↗
98. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy10.1021/nn405724x ↗
99. Biomimetic and bioinspired nano-platforms for cancer vaccine development10.1002/EXP.20210263 ↗
100. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor10.2147/IJN.S143264 ↗